Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics focuses on creating precision small molecules that seek to alter the course of clinical impairment, specializing in the neuroscience, inflammation, and immunology sectors.

CTNM

COM:CONTINEUM-TX

Contineum Therapeutics

Last Close

13.65

21/11 19:27

Market Cap

541.73M

Beta: -

Volume Today

25.42K

Avg: -